Abstract:Abstract Individuals with severe atopic dermatitis (AD) may present with very high serum IgE levels (> 10 000 IU mL−1). Signal transducer and activator of transcription 3 hyper-IgE syndrome (STAT3-HIES), a rare immunosuppressive disorder, shares pathogenic similarities with AD, involving dysregulation in the STAT3 signalling pathway and clinical, genetic and serological features similar to AD. Despite these parallels, patients with AD with very high IgE levels are not routinely tested for genetic overlap with STAT3-HIES. This might be relevant in therapeutic intervention. We reviewed the literature to identify individuals with possible overlap of both conditions to help identify a novel mixed phenotype (AD/STAT3-HIES). Intervention with Janus kinase (JAK) inhibitors in this subgroup might be beneficial given their shared dysregulation in STAT3 signalling pathways. This review investigates the identification of the AD/STAT3-HIES phenotype and its response to Janus kinase (JAK) inhibitors. A literature review was undertaken on PubMed, Scopus, Ovid and Google Scholar. Search terms included ‘atopic dermatitis’, ‘hyper-IgE syndrome’, ‘HIES’, ‘Job syndrome’, ‘STAT3’, ‘JAK/STAT pathway’ and ‘Janus kinase inhibitors’. Inclusion criteria were studies published in English between January 2005 and December 2023 relevant to the clinical features, treatment, pathogenesis and genetics of AD or STAT3-HIES. Out of 152 studies identified during the search, 29 met the inclusion criteria. The Table outlines the features of AD, STAT3-HIES and areas of overlap (AD/STAT3-HIES). Clinically, AD and STAT3-HIES share characteristics including eczematous lesions and staphylococcal skin infections. STAT3-HIES is distinguished from AD by the presence of immunoparesis and extracutaneous manifestations. Both diseases commonly exhibit elevated IgE levels. In severe AD, studies reported IgE levels ranging from 356 to 2379 IU mL−1, while patients with STAT3-HIES demonstrated levels between 1000 and 46 850 IU mL−1. Genetically, both diseases are associated with the STAT3 and IL6 genes. JAK inhibitors proved effective in treating AD in multiple studies. To date, only one ex vivo study suggested a potential treatment utility of JAK inhibitors in dominant negative STAT3 mutation. We postulate that patients with AD with elevated IgE levels beyond the typical range may benefit from further genotyping (STAT3 and IL6 gene mutations) to identify the AD/STAT3-HIES phenotype. Future clinical trials could assess the potential benefits of targeted intervention with JAK inhibitors in this subgroup and/or in patients with AD with very high serum IgE.ADAD/STAT3-HIESSTAT3-HIESClinicalPruritic eczematous lesionsPruritic eczematous lesionsPruritic eczematous lesionsStaphylococcal skin infectionsStaphylococcal skin infectionsStaphylococcal skin infectionsCold staphylococcal abscessRecurrent pneumoniaSkeletal and dental abnormalitiesConnective tissue abnormalitiesSerologyElevated IgEElevated IgEElevated IgEGenetic associationsSTAT3STAT3STAT3IL6RIL6RIL6RFLGIL6STIL2/IL21ZNF341IL7RTYK2IL15RA/IL2RAImmunologicalElevated interleukin-4Elevated interleukin-4Elevated interleukin-4Elevated interleukin-13Elevated interleukin-13Elevated interleukin-13

Mutation analysis of the STAT3 gene in a patient with hyper-IgE syndrome

STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway

The Clinical, Immunological and Genetic Features of 12 Chinese Patients with STAT3 Mutations

A Novel STAT3 Mutation in a Patient with Hyper-IgE Syndrome Diagnosed with a Severe Necrotizing Pulmonary Infection

Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review

Dysregulated Airway Host Defense in Hyper IgE Syndrome due to STAT3 Mutations

The STAT3 HIES Mutation is a Gain-of-function Mutation That Activates Genes Via AGG-element Carrying Promoters.

Defective Toll-Like Receptors Driven B Cell Response in Hyper IgE Syndrome Patients With <i>STAT3</i> Mutations

[Identification of FIP1L1-PDGFRA Fusion, and Expression of Signal Transducer and Activator of Transcription 5 in Hypereosinophilic Syndrome].

Defective Toll-Like Receptors Driven B Cell Response in Hyper IgE Syndrome Patients With STAT3 Mutations

X-linked Hyper-Igm Syndrome with Eosinophilia in a Male Child: A Case Report

Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome

Unraveling the unphosphorylated STAT3-unphosphorylated NF-κB pathway in loss of function STAT3 Hyper IgE syndrome

Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review

Severe Allergic Dysregulation Due to A Gain of Function Mutation in the Transcription Factor STAT6

Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome

Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome

PA03 Should patients with atopic dermatitis be screened for genes associated with hyper-IgE syndrome?

The characteristics of clinical manifestations, gene mutations and B lymphocytes differentiation of AD-HIES Children

Disseminated Talaromyces Marneffei Infection with STAT3-Hyper-IgE Syndrome: A Case Series and Literature Review

Obstructive uropathy in STAT 3 hyper immunoglobulin E syndrome: A 5 year old Middle Eastern boy